Neuren Pharmaceuticals Crescita futura

Future criteri di controllo 1/6

Si prevede che i ricavi di Neuren Pharmaceuticals diminuiranno a 5.1% all'anno, mentre si prevede che i suoi utili annuali cresceranno a 5.1% all'anno. Si prevede che l'EPS crescerà di 4.8% all'anno. Si prevede che il ritorno sul capitale proprio sarà 14% in 3 anni.

Informazioni chiave

5.1%

Tasso di crescita degli utili

4.79%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	41.1%
Tasso di crescita dei ricavi	-5.1%
Rendimento futuro del capitale proprio	14.02%
Copertura analitica	Good
Ultimo aggiornamento	09 May 2025

Aggiornamenti recenti sulla crescita futura

Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

Aug 29

Recent updates

Neuren Pharmaceuticals Limited (ASX:NEU) Shares Fly 30% But Investors Aren't Buying For Growth

May 16

DAYBUE And NNZ-2591 Will Expand Markets While Facing Regulatory Risks

Apr 23 Strong financial position and partnerships reduce the need for capital raising, protecting margins and earnings.

Investors Don't See Light At End Of Neuren Pharmaceuticals Limited's (ASX:NEU) Tunnel

Apr 01

A Look At The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Feb 06

Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Is Well Worth Watching

Jan 15

New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)

Nov 11

Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up

Nov 08

Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Oct 24

Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

Aug 29

Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now

Aug 14

Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today

May 31

Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely

May 03

An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Apr 01

Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Mar 05

Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Mar 02

Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Dec 18

Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Sep 02

Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Aug 31

This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Mar 03

Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

Jan 07

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Sep 06

Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

May 31

We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Feb 03

Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

Aug 06

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

May 05

Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Feb 19

Previsioni di crescita degli utili e dei ricavi

ASX:NEU - Stime future degli analisti e dati finanziari passati (AUD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2027	176	76	54	47	3
12/31/2026	142	55	23	50	4
12/31/2025	66	16	89	121	4
12/31/2024	217	142	-11	-11	N/A
9/30/2024	205	130	54	54	N/A
6/30/2024	193	117	119	120	N/A
3/31/2024	213	137	152	152	N/A
12/31/2023	232	157	185	185	N/A
9/30/2023	155	106	120	120	N/A
6/30/2023	78	55	54	54	N/A
3/31/2023	47	28	29	29	N/A
12/31/2022	15	0	4	4	N/A
9/30/2022	9	-3	-3	-3	N/A
6/30/2022	3	-7	-10	-10	N/A
3/31/2022	3	-7	-10	-10	N/A
12/31/2021	3	-8	-10	-10	N/A
9/30/2021	2	-10	-10	-10	N/A
6/30/2021	1	-12	-9	-9	N/A
3/31/2021	1	-11	-9	-9	N/A
12/31/2020	1	-9	-8	-8	N/A
9/30/2020	1	-8	-9	-9	N/A
6/30/2020	0	-8	-9	-9	N/A
3/31/2020	0	-9	-10	-10	N/A
12/31/2019	0	-11	-12	-12	N/A
9/30/2019	7	-6	-5	-5	N/A
6/30/2019	14	-1	2	2	N/A
3/31/2019	14	1	4	4	N/A
12/31/2018	14	3	6	6	N/A
9/30/2018	7	3	N/A	0	N/A
6/30/2018	1	3	N/A	-6	N/A
3/31/2018	1	3	N/A	-6	N/A
12/31/2017	1	3	N/A	-6	N/A
9/30/2017	2	-2	N/A	-7	N/A
6/30/2017	3	-8	N/A	-8	N/A
3/31/2017	3	-10	N/A	-10	N/A
12/31/2016	3	-12	N/A	-12	N/A
9/30/2016	2	-14	N/A	-14	N/A
6/30/2016	0	-15	N/A	-17	N/A
3/31/2016	1	-14	N/A	-15	N/A
12/31/2015	2	-13	N/A	-13	N/A
9/30/2015	2	-11	N/A	-11	N/A
6/30/2015	3	-9	N/A	-8	N/A
3/31/2015	3	-9	N/A	-7	N/A
12/31/2014	3	-8	N/A	-6	N/A
9/30/2014	3	-10	N/A	-7	N/A
6/30/2014	3	-12	N/A	-7	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di NEU ( 5.1% all'anno) è superiore al tasso di risparmio ( 3% ).

Guadagni vs Mercato: Si prevede che gli utili di NEU ( 5.1% all'anno) cresceranno più lentamente rispetto al mercato Australian ( 11.8% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di NEU cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che i ricavi di NEU diminuiranno nei prossimi 3 anni ( -5.1% all'anno).

Ricavi ad alta crescita: Si prevede che i ricavi di NEU diminuiranno nei prossimi 3 anni ( -5.1% all'anno).

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di NEU sarà basso tra 3 anni ( 14 %).

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2025/05/23 08:54
Prezzo dell'azione a fine giornata	2025/05/23 00:00
Guadagni	2024/12/31
Guadagni annuali	2024/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Neuren Pharmaceuticals Limited è coperta da 9 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Russell Wright	Barclay Pearce Capital Pty Limited
Melissa Benson	Barrenjoey Markets Pty Limited
Thomas Wakim	Bell Potter

Neuren Pharmaceuticals Crescita futura

Future criteri di controllo 1/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus EPS estimates increase by 27%

Price target decreased by 7.5% to AU$24.97

Consensus revenue estimates fall by 46%

Consensus revenue estimates increase by 17%, EPS downgraded

Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

Price target decreased by 7.5% to AU$26.54

Recent updates

Neuren Pharmaceuticals Limited (ASX:NEU) Shares Fly 30% But Investors Aren't Buying For Growth

Consensus EPS estimates increase by 27%

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Neuren Pharmaceuticals Limited, Annual General Meeting, May 27, 2025

DAYBUE And NNZ-2591 Will Expand Markets While Facing Regulatory Risks

Independent Non-Executive Director recently bought AU$153k worth of stock

Investor sentiment deteriorates as stock falls 20%

Investors Don't See Light At End Of Neuren Pharmaceuticals Limited's (ASX:NEU) Tunnel

Price target decreased by 7.5% to AU$24.97

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates fall by 46%

Neuren Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Feb 28, 2025

A Look At The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Investor sentiment improves as stock rises 27%

Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Is Well Worth Watching

Investor sentiment deteriorates as stock falls 26%

Now 24% undervalued

New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up

Investor sentiment improves as stock rises 17%

Consensus revenue estimates increase by 17%, EPS downgraded

New major risk - Revenue and earnings growth

Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

First half 2024 earnings: EPS misses analyst expectations

Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now

Price target decreased by 7.5% to AU$26.54

New major risk - Revenue and earnings growth

Investor sentiment deteriorates as stock falls 15%

Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today

Price target increased by 7.9% to AU$28.19

Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome

Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely

Neuren Pharmaceuticals Limited, Annual General Meeting, May 28, 2024

An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Consensus revenue estimates increase by 15%

Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Neuren Pharmaceuticals Limited to Report Q4, 2023 Results on Feb 29, 2024

Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Price target increased by 27% to AU$24.22

Investor sentiment improves as stock rises 40%

Consensus EPS estimates fall by 11%

Investor sentiment improves as stock rises 20%

Now 23% undervalued after recent price drop

Price target increased by 18% to AU$19.14

Now 20% undervalued after recent price drop

Consensus revenue estimates increase by 24%

Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Now 25% undervalued after recent price drop

Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023

Neuren Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023

Now 21% undervalued

Consensus EPS estimates fall by 12%

Price target increased by 8.3% to AU$15.07

Independent Non-Executive Director recently sold AU$15m worth of stock

Consensus revenue estimates increase by 12%, EPS downgraded

Price target increased by 18% to AU$10.60

Consensus EPS estimates fall by 14%

This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Price target increased by 12% to AU$8.99

Neuren Pharmaceuticals Limited Announces Prader-Willi Syndrome IND for NNZ-2591 Approval by FDA

Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

Neuren Pharmaceuticals Submits Investigational New Drug & First Patients Complete Phase 2 Trials

Price target increased to AU$7.83

Price target increased to AU$7.83

Price target increased to AU$7.37